Addus HomeCare reported third-quarter 2026 revenue of $387.7 million, up 7% from $362.3 million a year earlier. Adjusted earnings per share rose 17.3% to $1.83. Adjusted EBITDA grew 13.5% to $51.2 million, with the margin widening to 13.2% from 12.5%. Personal care same-store revenue rose 6.9%, and hospice same-store revenue rose 4.1%. The company agreed to buy AccentCare's personal care assets, excluding New York, for $275 million. The deal adds about $280 million in annualised revenue across 10 states and is expected to close in the first quarter of 2027. Addus ended September with $98.5 million in cash and $24.3 million in bank debt. It expects its adjusted EBITDA margin to dip in 2027 as lower-margin personal care makes up more of its business.

Can Addus HomeCare (ADUS) compound wealth at scale? Published September 23, 2026 at 7:08 am EDT When examining a long-term compounder, astute market participants look past quarterly headlines to evaluate core operational drivers, margin stability, and pricing power. Addus HomeCare (NASDAQ:ADUS) embodies many classic characteristics of a durable portfolio holding: a sticky, non-franchise personal care delivery model, consistent organic growth, and a disciplined approach to capital allocation across fragmented regional markets. Underlying fundamentals remain anchored by favorable demographic tailwinds in non-medical home care and hospice services, positioning the company to absorb meaningful scale over time. That operational discipline is being put to the test. On September 14, Addus agreed to acquire the personal care division of AccentCare for an anticipated $275 million, a transaction poised to inject roughly $280 million in annualized revenue in a single move. Representing nearly a fifth of the company's current revenue base, this bolt-on acquisition dwarfs typical organic additions and arrives right on the heels of another solid quarterly earnings report. For long-term investors, the central question is whether management can integrate a footprint of this magnitude without diluting operational efficiency or overleveraging the balance sheet. A Bigger Home Care Machine The AccentCare operations serve an average daily census of about 13,700 customers spread across a 10-state footprint, which deepens Addus in four states where it already has scale, Texas, Illinois, California, and Arizona, while adding a foothold in six more: Colorado, Georgia, Minnesota, Pennsylvania, Tennessee, and Washington. The company is funding the purchase through its revolver and cash on hand rather than issuing new shares, and the acquisition covers only personal care, leaving AccentCare's hospice and home health operations out of the deal entirely. That expansion builds on a business that was already moving. Reported in its second-quarter earnings release on August 3, net service revenues rose 8.0% to $377.4 million, while adjusted EBITDA climbed 11.9% to $49.2 million. Personal care, which made up 78.4% of quarterly revenue, grew organically 6.8% from a year earlier, helped by state rate increases that topped 9.9% in Texas and 3.9% in Illinois earlier this year. Hospice care grew even faster, up 11.1% organically and accounting for 17.0% of revenue. Cash flow from operations came in at $40.0 million for the quarter, giving Addus room to fund a deal of this size without straining its balance sheet. The price of growing fast. The AccentCare acquisition has not closed yet. It still needs regulatory approval and has to clear customary closing conditions, so nothing about the added $280 million in revenue is locked in. Drawing on the revolver to pay for it adds to a balance sheet that, while light on debt today at $64.3 million, will carry more leverage once the deal funds. The purchase also only picks up personal care operations spread across ten states, which means folding in a geographically scattered book of business without any of AccentCare's hospice or home health infrastructure to lean on. Growth in the base business leans on decisions outside the company's control too. The Texas and Illinois rate increases that powered personal care's organic growth came from state programs, and there is no guarantee future increases arrive on the same schedule. Home health, the smallest of Addus's three service lines at just 4.6% of quarterly revenue, offers the least cushion if either of the larger segments slows. And the adjusted earnings figures that show the sharpest growth exclude acquisition expenses, stock-based compensation, and restructuring costs, all of which still show up in the GAAP numbers. What the market is pricing. Hedge fund ownership rose from 15 to 17 funds quarter over quarter, which points to funds adding rather than trimming the position. Short interest sits at 5.78% of float, enough to suggest a real if modest bear camp rather than an absence of skepticism. The stock trades at a forward P/E of 15.22, as of September 22, a multiple that does not scream aggressive growth expectations baked into the price. That combination reads as a market waiting to see whether the AccentCare deal delivers before it moves the stock much further. Where this leaves investors. Addus is trying to add nearly a fifth of its revenue base in one transaction while its existing personal care and hospice segments keep growing on their own. That is the tension worth watching: a company with a track record of digesting acquisitions taking on its largest one yet, funded with borrowed money against a deal that has not closed. For the bulls, it comes down to the deal clearing regulatory review cleanly and state rate increases continuing to flow. For the bears, it comes down to integration costs or a slowdown in reimbursement rates eating into the accretion Addus is promising. The forward P/E suggests the market has not fully priced either outcome yet.